Table 1 Characteristics of the study cohort at the beginning of follow-up
From: Epilepsy as a risk factor for hepatic encephalopathy in patients with cirrhosis: a cohort study
Epilepsy | Not epilepsy | p-value | |
|---|---|---|---|
Number of patients | 21 | 1099 | |
Men (%) | 18 (86 %) | 760 (69 %) | 0.10 |
Age (median, IQR) | 54 (45–59) | 57 (50–64) | 0.04 |
Cirrhosis etiology | 0.22 | ||
Alcohol alone (%) | 16 (76 %) | 634 (58 %) | |
Hepatitis C alone (%) | 1 (5 %) | 147 (13 %) | |
Other (%) | 4 (19 %) | 318 (29 %) | |
Diabetes (%) | 4 (19 %) | 256 (23 %) | 0.65 |
History of HE before randomization (%) | 4 (19 %) | 251 (23 %) | 0.68 |
MELD score (median, IQR) | 7.9 (4.6–11.3) | 11.4 (8.1–14.4) | 0.02 |
Sodium, mmol/L (median, IQR) | 136 (133–138) | 137 (134–139) | 0.34 |
Albumin, g/L (median, IQR) | 33 (29–37) | 33 (29–37) | 0.68 |
Lactulose, any dose (%) | 14 (19 %) | 330 (30 %) | 0.28 |
Rifaximin, any dose (%) | 0 (0 %) | 27 (2 %) | 0.45 |
Benzodiazepine/barbiturates, any dose (%) | 2 (10 %) | 95 (9 %) | 0.89 |